Search
Home
Latest
News
North America
Europe
Asia
Middle East
Global
Fortune 500
Fortune 500 U.S.
Fortune Global 500
Fortune 500 Europe
Fortune China 500
Fortune SEA 500
Finance
Economy
Banking
Personal Finance
Investing
Real Estate
Energy
Crypto
Tech
Big Tech
Startups & Venture
AI
Innovation
Cybersecurity
Leadership
Future Of Work
Success
C-Suite
Workplace Culture
CEO Initiative
Lifestyle
Arts & Entertainment
Health
Travel & Leisure
Education
Rankings
Great Place To Work
Analytics
Multimedia
Live Media
Magazine
Newsletters
Press Releases
Video
Podcasts
Home
Latest
Latest
News
North America
Europe
Asia
Middle East
Global
Fortune 500
Fortune 500
Fortune 500 U.S.
Fortune Global 500
Fortune 500 Europe
Fortune China 500
Fortune SEA 500
Finance
Finance
Economy
Banking
Personal Finance
Investing
Real Estate
Energy
Crypto
Tech
Tech
Big Tech
Startups & Venture
AI
Innovation
Cybersecurity
Leadership
Leadership
Future Of Work
Success
C-Suite
Workplace Culture
CEO Initiative
Lifestyle
Lifestyle
Arts & Entertainment
Health
Travel & Leisure
Education
Rankings
Rankings
Great Place To Work
Analytics
Multimedia
Multimedia
Live Media
Magazine
Newsletters
Press Releases
Video
Podcasts
home
home
GLP-1s
GLP-1s
Health
GLP-1s could end up being ‘the first true longevity drug’ as the world battles a rising obesity crisis
By
Angelica Ang
November 21, 2025
C-Suite
Ray Dalio is backing a $1 billion blueberry unicorn that sells berries nearly the size of golf balls
By
Eva Roytburg
November 4, 2025
Health
Adult obesity rate fell from record high—and big pharma is reaping the benefits from mainstream sales of weight-loss drugs like Zepound and Mounjaro
By
Matty Merritt
and
Morning Brew
October 31, 2025
Economy
The ‘quiet alarm bell’ on U.S. health costs: Employers are backed into a corner, and workers are paying the price
By
Ashley Lutz
October 22, 2025
Commentary
Trump wants Medicare to pay for your Ozempic treatment. Taxpayers may foot the bill for billions in fraud
By
Ari Yampolsky
and
Max Voldman
August 12, 2025
Newsletters
Exclusive: The founders of SoulCycle built a startup for relationships, then pivoted to GLP-1 support groups. Now its assets are being acquired by WeightWatchers
By
Emma Hinchliffe
August 7, 2025
Newsletters
Behold, an AI model from OpenAI that’s…open
By
Andrew Nusca
August 6, 2025
Health
Weight-loss drugs should be first step to prevent heart disease, top cardiology group says
By
Michelle Amponsah
and
Bloomberg
June 20, 2025
Lifestyle
Agency warns that weight-loss drugs can decrease effectiveness of birth control pills
By
Beth Greenfield
June 5, 2025
Health
The Ozempic boom could be bad news for restaurants as more than half of GLP-1 users report cutting back on dining out, report finds
By
Sasha Rogelberg
June 4, 2025
Commentary
The crisis over GLP-1 out-of-pocket costs deepens—it’s time for health-care leaders to step up
By
Wendy Barnes
March 4, 2025
Health
50-year-old security guard lost 70 pounds on Wegovy—then gained two pants sizes when he lost insurance coverage
By
Tom Murphy
and
The Associated Press
February 24, 2025
Health
Wegovy, Ozempic shortage declared over, hitting copycats like Hims & Hers
By
Bloomberg
,
Madison Muller
,
Ike Swetlitz
and
Naomi Kresge
February 21, 2025
Health
Ozempic, Wegovy maker calls out Hims & Hers Super Bowl ad: ‘Check before you inject’
By
Lindsey Leake
February 11, 2025
Health
Merck touts 20 new ‘blockbuster’ drugs in development with $50 billion potential
By
Hallie Steiner
February 4, 2025
Most Popular
Law
Amazon is cutting checks to millions of customers as part of a $2.5 billion FTC settlement. Here's who qualifies and...
By
Sydney Lake
Future of Work
AI layoffs are looking more and more like corporate fiction that's masking a darker reality, Oxford Economics suggests
By
Nick Lichtenberg
Success
Diary of a CEO founder says he hired someone with 'zero' work experience because she 'thanked the security guard by...
By
Emma Burleigh